Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen D Smith

Showing results (91-100 of 159) with videos related to

Pageof 16
Sort By:
Journal of the International Neuropsychological Society : JINS|December 5, 2009
Amygdala activation to masked happy facial expressionsMario F Juruena, Vincent P Giampietro, Stephen D Smith, et al.
Future Oncology (London, England)|September 28, 2020
A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphomaMartin Dreyling, Constantine S Tam, Michael Wang, et al.
British Journal of Haematology|June 23, 2020
Addressing the conundrum of male predominance in mantle cell lymphoma using androgen receptor blockadeVictor A Chow, Paul S Martin, Stephen D Smith, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 10, 2018
Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell LymphomaStephen D Smith, Shruti Gandhy, Ajay K Gopal, et al.
Leukemia & Lymphoma|February 24, 2022
Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphomaPaul M Barr, Stephen D Smith, Mark J Roschewski, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 22, 2014
Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective studyEmma C Scott, Stephen B Heitner, William Dibb, et al.
British Journal of Haematology|March 18, 2011
Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centresStephen D Smith, Craig H Moskowitz, Robert Dean, et al.
British Journal of Haematology|October 14, 2009
Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposideRobert M Dean, Brad Pohlman, John W Sweetenham, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 8, 2025
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular LymphomaChaitra Ujjani, Hongkun Wang, Catherine Broome, et al.
British Journal of Haematology|October 10, 2025
Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphomaRyan C Lynch, Ryan D Cassaday, Stephen D Smith, et al.
Pageof 16

Showing results (91-100 of 159) with videos related to

Sort By:
Pageof 16
Journal of the International Neuropsychological Society : JINS|December 5, 2009
Amygdala activation to masked happy facial expressionsMario F Juruena, Vincent P Giampietro, Stephen D Smith, et al.
Future Oncology (London, England)|September 28, 2020
A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphomaMartin Dreyling, Constantine S Tam, Michael Wang, et al.
British Journal of Haematology|June 23, 2020
Addressing the conundrum of male predominance in mantle cell lymphoma using androgen receptor blockadeVictor A Chow, Paul S Martin, Stephen D Smith, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 10, 2018
Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell LymphomaStephen D Smith, Shruti Gandhy, Ajay K Gopal, et al.
Leukemia & Lymphoma|February 24, 2022
Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphomaPaul M Barr, Stephen D Smith, Mark J Roschewski, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 22, 2014
Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective studyEmma C Scott, Stephen B Heitner, William Dibb, et al.
British Journal of Haematology|March 18, 2011
Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centresStephen D Smith, Craig H Moskowitz, Robert Dean, et al.
British Journal of Haematology|October 14, 2009
Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposideRobert M Dean, Brad Pohlman, John W Sweetenham, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 8, 2025
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular LymphomaChaitra Ujjani, Hongkun Wang, Catherine Broome, et al.
British Journal of Haematology|October 10, 2025
Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphomaRyan C Lynch, Ryan D Cassaday, Stephen D Smith, et al.
Pageof 16